We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+3.44%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$327M
AUM Growth
-$2.9M
Cap. Flow
-$9.1M
Cap. Flow %
-2.78%
Top 10 Hldgs %
34.51%
Holding
107
New
22
Increased
29
Reduced
23
Closed
32

Top Buys

Rank Stock Value
1
WBA
Walgreens Boots Alliance
WBA
+$10.3M
2
MDT icon
Medtronic
MDT
+$7.09M
3
WMGI
Wright Medical Group Inc
WMGI
+$6.55M
4
AGN
Allergan plc
AGN
+$6.46M
5
MRK icon
Merck
MRK
+$6.16M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$8.12M
2
UHS icon
Universal Health Services
UHS
+$7.89M
3
BIIB icon
Biogen
BIIB
+$7.83M
4
BCR
CR Bard Inc.
BCR
+$5.49M
5
NSTG
NanoString Technologies, Inc.
NSTG
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 86.13%
2 Real Estate 3.64%
3 Financials 2.17%
4 Technology 0.3%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
51
Ascendis Pharma A/S
ASND
$16B
$1.51M 0.46%
37,828
+20,498
+118% +$745K
TCMD icon
52
Tactile Systems Technology
TCMD
$635M
$1.48M 0.45%
+50,900
New +$1.48M
EW icon
53
Edwards Lifesciences
EW
$49.6B
$1.38M 0.42%
36,648
+1,800
+5% +$66.1K
IMGN
54
DELISTED
Immunogen Inc
IMGN
$1.35M 0.41%
210,800
+132,300
+169% +$816K
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$1.31M 0.4%
41,400
+30,900
+294% +$970K
MDCO
56
DELISTED
Medicines Co
MDCO
$1.13M 0.34%
+41,200
New +$1.27M
VCRA
57
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$982K 0.3%
+32,500
New +$927K
ANAB icon
58
AnaptysBio
ANAB
$1.58B
$977K 0.3%
9,700
-14,900
-61% -$1.1M
RNTX
59
Rein Therapeutics
RNTX
$63.1M
$906K 0.28%
4,300
+832
+24% +$199K
BMRN icon
60
BioMarin Pharmaceuticals
BMRN
$11.6B
$901K 0.28%
+10,100
New +$878K
AKTX
61
Akari Therapeutics
AKTX
$13.8M
$871K 0.27%
+251
New +$968K
ZGNX
62
DELISTED
Zogenix, Inc.
ZGNX
$801K 0.24%
+20,000
New +$768K
INSM icon
63
Insmed
INSM
$21.4B
$714K 0.22%
22,910
-72,490
-76% -$2.14M
INCY icon
64
Incyte
INCY
$24.2B
$703K 0.21%
7,420
-14,180
-66% -$1.48M
RVTY icon
65
Revvity
RVTY
$12.6B
$688K 0.21%
+9,405
New +$675K
JAZZ icon
66
Jazz Pharmaceuticals
JAZZ
$15.9B
$667K 0.2%
4,950
-13,500
-73% -$1.87M
ARRY
67
DELISTED
Array Biopharma Inc
ARRY
$648K 0.2%
50,600
-40,400
-44% -$460K
OMED
68
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$570K 0.17%
+139,100
New +$605K
ASMB icon
69
Assembly Biosciences
ASMB
$498M
$430K 0.13%
+792
New +$359K
CI icon
70
Cigna
CI
$73.7B
$406K 0.12%
2,000
-14,700
-88% -$2.93M
APLS
71
DELISTED
Apellis Pharmaceuticals
APLS
$382K 0.12%
+17,600
New +$259K
SPRO icon
72
Spero Therapeutics
SPRO
$67.7M
$365K 0.11%
+31,100
New +$382K
BHVN
73
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$278K 0.09%
+10,300
New +$284K
DRNA
74
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$170K 0.05%
+18,837
New +$139K
ANIP icon
75
ANI Pharmaceuticals
ANIP
$1.8B
– –
-59,900
Closed -$3.14M
1 2
3
4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Endurant Capital Management held 107 positions worth $327M, down 0.88% from $330M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Endurant Capital Management's Q4 2017 filing shows 22 new, 29 increased, 23 reduced and 32 closed positions. Its largest new stake was Merck: 111,193 shares worth $5.97M. The largest sale was Pfizer, an estimated $8.12M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 83% a quarter earlier, followed by Real Estate and Financials.

  • Endurant Capital Management's largest Q4 2017 buy was Merck: 111,193 shares worth $5.97M.
  • Endurant Capital Management added most to Walgreens Boots Alliance in Q4 2017, an estimated $10.3M increase.
  • Endurant Capital Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $7.83M.
  • Endurant Capital Management fully exited Pfizer in Q4 2017, selling an estimated $8.12M.
  • Endurant Capital Management's ten largest holdings make up 35% of its $327M portfolio in Q4 2017.
  • Endurant Capital Management opened 22 new positions and closed 32 in Q4 2017.
  • Endurant Capital Management's portfolio value fell 0.88% quarter-over-quarter to $327M.

Based on Endurant Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.